| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Abstracts of the Cancer Cachexia Conference, Boston, USA, 21–23 September 2012
|
|
|
2012
|
|
4 |
p. 281-301
|
article
|
| 2 |
Abstracts of the 7th Cachexia Conference, Kobe/Osaka, Japan, December 9–11, 2013
|
|
|
2013
|
|
4 |
p. 295-343
|
article
|
| 3 |
Abstracts of the 6th Cachexia Conference, Milan, Italy, December 8–10, 2011
|
|
|
2011
|
|
4 |
p. 209-261
|
article
|
| 4 |
Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile
|
Pietra, Claudio
|
|
2014
|
|
4 |
p. 329-337
|
article
|
| 5 |
Anorexia/cachexia of chronic diseases: a role for the TGF-β family cytokine MIC-1/GDF15
|
Tsai, Vicky W. W.
|
|
2012
|
|
4 |
p. 239-243
|
article
|
| 6 |
Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial
|
Rattanasompattikul, Manoch
|
|
2013
|
|
4 |
p. 247-257
|
article
|
| 7 |
A pilot study of temsirolimus and body composition
|
Veasey-Rodrigues, Heloisa
|
|
2013
|
|
4 |
p. 259-265
|
article
|
| 8 |
Attenuation of muscle wasting in murine C2C12 myotubes by epigallocatechin-3-gallate
|
Mirza, Kamran A.
|
|
2014
|
|
4 |
p. 339-345
|
article
|
| 9 |
Bile acids for cachexia therapy
|
Tschirner, Anika
|
|
2012
|
|
4 |
p. 279
|
article
|
| 10 |
Cachexia: a problem of energetic inefficiency
|
Argilés, Josep M.
|
|
2014
|
|
4 |
p. 279-286
|
article
|
| 11 |
Cachexia vs obesity: where is the real unmet clinical need?
|
Haehling, Stephan von
|
|
2013
|
|
4 |
p. 245-246
|
article
|
| 12 |
Cancer cachexia and anabolic interventions: a case report
|
Dillon, Edgar L.
|
|
2012
|
|
4 |
p. 253-263
|
article
|
| 13 |
Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency
|
Julienne, Cloé M.
|
|
2012
|
|
4 |
p. 265-275
|
article
|
| 14 |
Consilience in sarcopenia of cirrhosis
|
Dasarathy, Srinivasan
|
|
2012
|
|
4 |
p. 225-237
|
article
|
| 15 |
Disruption of pro-oxidant and antioxidant systems with elevated expression of the ubiquitin proteosome system in the cachectic heart muscle of nude mice
|
Hinch, E. C. A.
|
|
2013
|
|
4 |
p. 287-293
|
article
|
| 16 |
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
|
Fogelman, David R.
|
|
2014
|
|
4 |
p. 307-313
|
article
|
| 17 |
Erratum to: Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure
|
Khawaja, Tuba
|
|
2014
|
|
4 |
p. 349
|
article
|
| 18 |
Formoterol in the treatment of experimental cancer cachexia: effects on heart function
|
Toledo, Míriam
|
|
2014
|
|
4 |
p. 315-320
|
article
|
| 19 |
From muscle wasting to sarcopenia and myopenia: update 2012
|
Haehling, Stephan von
|
|
2012
|
|
4 |
p. 213-217
|
article
|
| 20 |
Growth hormone, insulin-like growth factor 1, and insulin signaling—a pharmacological target in body wasting and cachexia
|
Trobec, Katja
|
|
2011
|
|
4 |
p. 191-200
|
article
|
| 21 |
Modeling human cancer cachexia in colon 26 tumor-bearing adult mice
|
Talbert, Erin E.
|
|
2014
|
|
4 |
p. 321-328
|
article
|
| 22 |
Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers
|
Utech, Anne E.
|
|
2012
|
|
4 |
p. 245-251
|
article
|
| 23 |
Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014
|
Haehling, Stephan von
|
|
2014
|
|
4 |
p. 261-263
|
article
|
| 24 |
Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology—update 2014
|
Morley, John E.
|
|
2014
|
|
4 |
p. 253-259
|
article
|
| 25 |
Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management
|
Wakabayashi, Hidetaka
|
|
2014
|
|
4 |
p. 269-277
|
article
|
| 26 |
Relation of respiratory muscle strength, cachexia and survival in severe chronic heart failure
|
Habedank, Dirk
|
|
2013
|
|
4 |
p. 277-285
|
article
|
| 27 |
Research on cachexia, sarcopenia and skeletal muscle in cardiology
|
Coats, Andrew J. S.
|
|
2012
|
|
4 |
p. 219-223
|
article
|
| 28 |
Sarcopenia: describing rather than defining a condition
|
Alchin, David Rhys
|
|
2014
|
|
4 |
p. 265-268
|
article
|
| 29 |
Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones
|
Josiak, Krystian
|
|
2014
|
|
4 |
p. 287-296
|
article
|
| 30 |
Synemin: an evolving role in tumor growth and progression
|
Kapoor, Shailendra
|
|
2013
|
|
4 |
p. 347-348
|
article
|
| 31 |
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design
|
Stewart Coats, Andrew J.
|
|
2011
|
|
4 |
p. 201-207
|
article
|
| 32 |
The 6th Cachexia Conference: an introduction to clinical and basic research in an exiting area
|
Haehling, Stephan von
|
|
2011
|
|
4 |
p. 189-190
|
article
|
| 33 |
Type VI collagen turnover-related peptides—novel serological biomarkers of muscle mass and anabolic response to loading in young men
|
Nedergaard, Anders
|
|
2013
|
|
4 |
p. 267-275
|
article
|
| 34 |
Ursodeoxycholic acid and its emerging role in attenuation of tumor growth in gastrointestinal malignancies
|
Kapoor, Shailendra
|
|
2012
|
|
4 |
p. 277-278
|
article
|
| 35 |
Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure
|
Khawaja, Tuba
|
|
2014
|
|
4 |
p. 297-305
|
article
|
Journal description